Genentech’s large-scale manufacturing project in Holly Springs, North Carolina, represents one of the most significant biopharmaceutical investments currently underway in the United States. Originally announced in 2025 as a $700 million facility, the project has since evolved into a far larger and more strategic development, with total investment now reaching approximately $2 billion. The expansion reflects both the accelerating demand for advanced biologic medicines and a broader shift toward strengthening domestic pharmaceutical manufacturing capacity.

Located in Holly Springs, within the Research Triangle region, the facility marks Genentech’s first manufacturing site on the U.S. East Coast. The project forms part of parent company Roche’s long-term strategy to expand its U.S. manufacturing and research footprint, positioning the site as a key node in a nationwide network of biopharmaceutical production and innovation.

Project Evolution and Strategic Expansion

The Holly Springs development has progressed through multiple phases in a relatively short timeframe. Genentech first announced its entry into the region in May 2025, followed by groundbreaking in August 2025. By January 2026, the company significantly expanded the scope of the project, more than doubling its original capital commitment.

This additional investment is being used to scale production capacity through the buildout of additional manufacturing lines and supporting infrastructure. The expansion enables the facility to handle greater output volumes and more complex biologic production processes, ensuring it can meet long-term demand for next-generation therapies.

The facility is expected to become operational by 2029, with phased ramp-up likely as production systems and regulatory approvals come online.

Manufacturing Focus and Technology

The Holly Springs site is being designed as a state-of-the-art biomanufacturing facility focused on producing advanced biologic medicines. These therapies differ from traditional pharmaceuticals in that they are derived from living cells and require highly specialized production environments, including sterile processing, precision control systems, and advanced automation.

A key focus of the facility will be treatments targeting metabolic diseases, including obesity and related conditions such as diabetes. These therapies are among the fastest-growing segments in the global pharmaceutical market, driven by rising prevalence rates and increasing demand for more effective treatment options.

To support this, the plant will incorporate modern bioprocessing technologies, digital manufacturing systems, and automation platforms aimed at improving efficiency, scalability, and consistency. The expanded investment also allows Genentech to integrate more resilient supply chain capabilities, reducing reliance on external production and improving responsiveness to market demand.

Economic Impact and Job Creation

The expansion has significantly increased the project’s economic impact. At full scale, the development is expected to support more than 500 high-wage manufacturing jobs, alongside over 1,500 construction jobs during the build phase. These roles span a wide range of functions, including process engineering, quality control, operations, and technical support.

Manufacturing positions at the facility are expected to offer competitive compensation, with average annual salaries estimated at approximately $120,000. In addition to direct employment, the project is expected to generate broader economic benefits across the region through supply chain activity, service demand, and workforce development initiatives.

Local and state governments have played a key role in enabling the project, providing incentives and infrastructure support. Combined incentives from Holly Springs and Wake County are estimated at approximately $33 million, reflecting the scale and strategic importance of the investment.

Regional Context: A Growing Life Sciences Hub

Genentech’s decision to expand in Holly Springs is closely tied to the strengths of the broader Research Triangle region. The area is widely recognized as one of the leading life sciences clusters in the United States, supported by a dense network of academic institutions, research organizations, and biotechnology companies.

Holly Springs, in particular, has emerged as a focal point for recent biomanufacturing investment. Companies such as CSL Seqirus, FUJIFILM Biotechnologies, and Amgen have all established significant operations in the area, contributing to a rapidly expanding ecosystem.

This concentration of industry activity provides several advantages, including access to a highly skilled workforce, proximity to research and development capabilities, and established infrastructure for advanced manufacturing. For Genentech, these factors reduce execution risk while enabling long-term scalability.

Ultimately, this East Coast anchor will play a crucial role in ensuring that Genentech’s breakthrough therapies can be developed, produced, and delivered to patients more efficiently than ever before. Yet another facility similar to this that was recently approved for construction is the BioMADE Biosmanufacturing Facility in Maple Grove. The project is funded by the U.S. Department of Defense and the Minnesota Department of Employment and Economic Development (DEED). Further, it will serve as a national model for scaling biotechnology innovations.

Public-Private Collaboration

The project has been supported by a broad network of public and institutional partners, reflecting a coordinated approach to economic development. Key stakeholders include Wake County Economic Development, the Economic Development Partnership of North Carolina, the North Carolina Community College System, and Wake Technical Community College, among others.

Workforce development has been a central component of this collaboration, with local institutions playing a role in training and preparing talent for highly specialized biomanufacturing roles. Utility providers such as Duke Energy and Enbridge Gas North Carolina are also supporting the infrastructure requirements of the facility.

This level of coordination highlights the importance of public-private partnerships in delivering large-scale advanced manufacturing projects, particularly in highly regulated and technically complex sectors such as biopharmaceuticals.

Long-Term Significance

The Holly Springs facility underscores a broader trend toward reshoring and expanding pharmaceutical manufacturing within the United States. By increasing domestic production capacity, companies like Genentech aim to enhance supply chain resilience, reduce dependency on international manufacturing, and ensure more reliable access to critical medicines.

At the same time, the project reflects the growing importance of biologics and next-generation therapies in the global healthcare landscape. Facilities of this scale and sophistication are essential to supporting the development and commercialization of these treatments.

As construction progresses and the facility moves toward its 2029 operational target, the Holly Springs site is expected to play a central role in both Genentech’s manufacturing network and the continued growth of North Carolina’s life sciences sector.

Project Factsheet

Project Name: Genentech Holly Springs Manufacturing Facility
Location: Holly Springs, North Carolina
Company: Genentech (Roche Group)

Total Investment: $2 billion (expanded from initial $700 million)
Project Type: Biopharmaceutical manufacturing facility
Site Size: 100 acres
Facility Scale: ~700,000 square feet (planned)

Key Milestones:

• Initial Announcement: May 2025
• Groundbreaking: August 2025
• Expansion Announcement: January 2026
• Operational Target: 2029

Manufacturing Focus:

• Biologic medicines
• Metabolic and obesity treatments
• Advanced bioprocessing and automation systems

Employment Impact:

• 500+ high-wage manufacturing jobs
• 1,500 construction jobs
• Avg. salary: ~$120,000 (manufacturing roles)

Incentives:

• $33 million (local + county support)

Key Partners & Stakeholders:

• Wake County Economic Development
• Economic Development Partnership of North Carolina
• Town of Holly Springs
• Wake County Government
• North Carolina Community College System
• Wake Technical Community College
• Capital Area Workforce Development Board
• Duke Energy
• Enbridge Gas North Carolina

Strategic Role:

• First Genentech East Coast manufacturing facility
• Supports Roche’s broader U.S. expansion strategy
• Strengthens domestic biopharmaceutical supply chains